ClinicalTrials.gg
Biological

Scorpion (centruroides) immune FAB2 antivenin (equine) clinical trials

Also written Anascorp.

studies test it
3
open now
0
in phase 3
3
first study started
2004

How each study uses scorpion (centruroides) immune FAB2 antivenin (equine) is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
3 Aug 2011 · Anascorp · BLA 125335 (FDA, Purple Book)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Antivenin Centruroides (scorpion) equine immune F(ab')2
2

Brand

Anascorp
3

Studies by the year they started

3 studies that test it; most in 2004 (2)

Studies that test scorpion (centruroides) immune FAB2 antivenin (equine), by start year
YearStudies
20042
20051

By phase

A phase 1/2 study counts in both.

Phase 2
1
Phase 3
3

Who runs them

Industry 3 · Other 0

Instituto Bioclon S.A. de C.V. (3)

Studies

Open first, then newest update. How each study uses scorpion (centruroides) immune FAB2 antivenin (equine) is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3